Laboratory Publications

An Adeno-Associated Virus-Based Intracellular Sensor of Pathological Nuclear Factor-kappa B Activation for Disease-Inducible Gene Transfer.

A. Chtarto, O. Bockstael, E. Gebara, K. Vermoesen, C. Melas, C. Pythoud, M. Levivier, O. De Witte, R. Luthi-Carter, R. Clinkers and L. Tenenbaum. in Plos One, vol. 8, num. 1, 2013.

MicroRNA-22 (miR-22) Overexpression Is Neuroprotective via General Anti-Apoptotic Effects and May also Target Specific Huntington's Disease-Related Mechanisms.

A. Jovicic, J. F. Z. Jolissaint, R. Moser, M. D. F. S. Santos and R. Luthi-Carter. in Plos One, vol. 8, num. 1, 2013.

MAP Kinase Phosphatase 1 (MKP-1/DUSP1) Is Neuroprotective in Huntington's Disease via Additive Effects of JNK and p38 Inhibition.

D. M. Taylor, R. Moser, E. Regulier, L. Breuillaud, M. Dixon, A. A. Beesen, L. Elliston, M. D. F. S. Santos, J. Kim, L. Jones, D. R. Goldstein, R. J. Ferrante and R. Luthi-Carter. in Journal Of Neuroscience, vol. 33, num. 6, p. 2313-2325, 2013.

Comparative analyses of Purkinje cell gene expression profiles reveal shared molecular abnormalities in models of different polyglutamine diseases.

B. Friedrich, P. Euler, R. Ziegler, A. Kuhn, B. G. Landwehrmeyer, R. Luthi-Carter, C. Weiller, S. Hellwig and B. Zucker. in Brain Research, vol. 1481, p. 37-48, 2012.

Genome-Wide Histone Acetylation Is Altered in a Transgenic Mouse Model of Huntington's Disease.

K. N. Mcfarland, S. Das, T. T. Sun, D. Leyfer, E. Xia, G. R. Sangrey, A. Kuhn, R. Luthi-Carter, T. W. Clark, G. Sadri-Vakili and J.-H. J. Cha. in Plos One, vol. 7, num. 7, 2012.

What have we learned from gene expression profiles in Huntington's disease?.

T. Seredenina and R. Luthi-Carter. in Neurobiology Of Disease, vol. 45, p. 83-98, 2012.

Gene expression profiling of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington's disease.

B. Tang, T. Seredenina, G. Coppola, A. Kuhn, D. H. Geschwind, R. Luthi-Carter and E. A. Thomas. in Neurobiology Of Disease, vol. 42, num. 3, p. 459-467, 2011.

A Brain-Permeable Small Molecule Reduces Neuronal Cholesterol by Inhibiting Activity of Sirtuin 2 Deacetylase.

D. M. Taylor, U. Balabadra, Z. Xiang, B. Woodman, S. Meade, A. Amore, M. M. Maxwell, S. Reeves, G. P. Bates, R. Luthi-Carter, P. A. S. Lowden and A. G. Kazantsev. in Acs Chemical Biology, vol. 6, num. 6, p. 540-546, 2011.

Decreased Striatal RGS2 Expression Is Neuroprotective in Huntington's Disease (HD) and Exemplifies a Compensatory Aspect of HD-Induced Gene Regulation.

T. Seredenina, O. Gokce and R. Luthi-Carter. in Plos One, vol. 6, p. -, 2011.

Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease.

J. Labbadia, H. Cunliffe, A. Weiss, E. Katsyuba, K. Sathasivam, T. Seredenina, B. Woodman, S. Moussaoui, S. Frentzel, R. Luthi-Carter, P. Paganetti and G. P. Bates. in Journal Of Clinical Investigation, vol. 121, num. 8, p. 3306-3319, 2011.

Synchrotron Infrared Microspectroscopy Detecting the Evolution of Huntington's Disease Neuropathology and Suggesting Unique Correlates of Dysfunction in White versus Gray Brain Matter.

M. Bonda, V. Perrin, B. Vileno, H. Runne, A. Kretlow, L. Forro, R. Luthi-Carter, L. M. Miller and S. Jeney. in Analytical Chemistry, vol. 83, num. 20, p. 7712-7720, 2011.

Population-specific expression analysis (PSEA) reveals molecular changes in diseased brain.

A. Kuhn, D. Thu, H. J. Waldvogel, R. L. M. Faull and R. Luthi-Carter. in Nature Methods, vol. 8, num. 11, p. 945-947, 2011.

Expression analysis of novel striatal-enriched genes in Huntington disease.

G. Mazarei, S. J. Neal, K. Becanovic, R. Luthi-Carter, E. M. Simpson and B. R. Leavitt. in Human Molecular Genetics, vol. 19, num. 4, p. 609-622, 2010.

Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis.

K. Becanovic, M. A. Pouladi, R. S. Lim, A. Kuhn, P. Pavlidis, R. Luthi-Carter, M. R. Hayden and B. R. Leavitt. in Human Molecular Genetics, vol. 19, num. 8, p. 1438-1452, 2010.

Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease.

D. C. V. Thu, D. E. Oorschot, L. J. Tippett, A. L. Nana, V. M. Hogg, B. J. Synek, R. Luthi-Carter, H. J. Waldvogel and R. L. M. Faull. in Brain, vol. 133, p. 1094-1110, 2010.

Developmental expression of Synaptotagmin isoforms in single calyx of Held-generating neurons.

L. Xiao, Y. Han, H. Runne, H. Murray, O. Kochubey, R. Luthi-Carter and R. Schneggenburger. in Molecular And Cellular Neuroscience, vol. 44, p. 374-385, 2010.

Environmental Enrichment Reduces Neuronal Intranuclear Inclusion Load But Has No Effect on Messenger RNA Expression in a Mouse Model of Huntington Disease.

C. L. Benn, R. Luthi-Carter, A. Kuhn, G. Sadri-Vakili, K. L. Blankson, S. C. Dalai, D. R. Goldstein, T. L. Spires, J. Pritchard, J. M. Olson, A. van Dellen, A. J. Hannan and J.-H. J. Cha. in Journal Of Neuropathology And Experimental Neurology, vol. 69, num. 8, p. 817-827, 2010.

Reply to Valenza and Cattaneo: SIRT2-mediated neuroprotection and cholesterol dyshomeostasis in Huntington's disease.

R. Luthi-Carter and A. G. Kazantsev. in Proceedings Of The National Academy Of Sciences Of The United States Of America, vol. 107, num. 37, p. 16000-16000, 2010.

Decreased Lin7b expression in layer 5 pyramidal neurons may contribute to impaired corticostriatal connectivity in huntington disease.

B. Zucker, J. A. Kama, A. Kuhn, D. Thu, L. R. Orlando, A. W. Dunah, O. Gokce, D. M. Taylor, J. Lambeck, B. Friedrich, K. S. Lindenberg, R. L. M. Faull, C. Weiller, A. B. Young and R. Luthi-Carter. in Journal of neuropathology and experimental neurology, vol. 69, num. 9, p. 880-95, 2010.

Diminished activity-dependent brain-derived neurotrophic factor expression underlies cortical neuron microcircuit hypoconnectivity resulting from exposure to mutant huntingtin fragments.

L. Gambazzi, O. Gokce, T. Seredenina, E. Katsyuba, H. Runne, H. Markram, M. Giugliano and R. Luthi-Carter. in The Journal of pharmacology and experimental therapeutics, vol. 335, num. 1, p. 13-22, 2010.

SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis.

R. Luthi-Carter, D. M. Taylor, J. Pallos, E. Lambert, A. Amore, A. Parker, H. Moffitt, D. L. Smith, H. Runne, O. Gokce, A. Kuhn, Z. Xiang, M. M. Maxwell, S. A. Reeves, G. P. Bates, C. Neri, L. M. Thompson, J. L. Marsh and A. G. Kazantsev. in Proceedings of the National Academy of Sciences of the United States of America, vol. 107, num. 17, p. 7927-32, 2010.

Sustained Effects of Nonallele-Specific Huntingtin Silencing.

V. Drouet, V. Perrin, R. Hassig, N. Dufour, G. Auregan, S. Alves, G. Bonvento, E. Brouillet, R. Luthi-Carter, P. Hantraye and N. Deglon. in Annals Of Neurology, vol. 65, num. 3, p. 276-285, 2009.

A Large Number of Protein Expression Changes Occur Early in Life and Precede Phenotype Onset in a Mouse Model for Huntington Disease.

C. Zabel, L. Mao, B. Woodman, M. Rohe, M. A. Wacker, Y. Klaere, A. Koppelstaetter, G. Nebrich, O. Klein, S. Grams, A. Strand, R. Luthi-Carter, D. Hartl, J. Klose and G. P. Bates. in Molecular & Cellular Proteomics, vol. 8, num. 4, p. 720-734, 2009.

Diminished hippocalcin expression in Huntington's disease brain does not account for increased striatal neuron vulnerability as assessed in primary neurons.

N. Rudinskiy, Y. A. Kaneko, A. A. Beesen, O. Gokce, E. Régulier, N. Déglon and R. Luthi-Carter. in Journal of neurochemistry, vol. 111, num. 2, p. 460-72, 2009.

Short-term striatal gene expression responses to brain-derived neurotrophic factor are dependent on MEK and ERK activation.

O. Gokce, H. Runne, A. Kuhn and R. Luthi-Carter. in PloS one, vol. 4, num. 4, p. e5292, 2009.

Calpain hydrolysis of alpha- and beta2-adaptins decreases clathrin-dependent endocytosis and may promote neurodegeneration.

N. Rudinskiy, Y. Grishchuk, A. Vaslin, J. Puyal, A. Delacourte, H. Hirling, P. G. H. Clarke and R. Luthi-Carter. in The Journal of biological chemistry, vol. 284, num. 18, p. 12447-58, 2009.

Cross-species and cross-platform gene expression studies with the Bioconductor-compliant R package 'annotationTools'..

A. Kuhn, R. Luthi-Carter and M. Delorenzi. in BMC bioinformatics, vol. 9, p. 26, 2008.

Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo.

D. Charvin, E. Roze, V. Perrin, C. Deyts, S. Betuing, C. Pages, E. Regulier, R. Luthi-Carter, E. Brouillet, N. Deglon and J. Caboche. in Neurobiology Of Disease, vol. 29, num. 1, p. 22-29, 2008.

Biological and Potential Therapeutic Roles of Sirtuin Deacetylases.

D. M. Taylor, M. M. Maxwell, R. Luthi-Carter and A. G. Kazantsev. in Cellular And Molecular Life Sciences, vol. 65, num. 24, p. 4000-4018, 2008.

Comprehensive spatiotemporal transcriptomic analyses of the ganglionic eminences demonstrate the uniqueness of its caudal subdivision.

S. Willi-Monnerat, E. Migliavacca, D. Surdez, M. Delorenzi, R. Luthi-Carter and A. V. Terskikh. in Molecular and cellular neurosciences, vol. 37, num. 4, p. 845-56, 2008.

Dysregulation of gene expression in primary neuron models of Huntington's disease shows that polyglutamine-related effects on the striatal transcriptome may not be dependent on brain circuitry.

H. Runne, E. Régulier, A. Kuhn, D. Zala, O. Gokce, V. Perrin, B. Sick, P. Aebischer, N. Déglon and R. Luthi-Carter. in The Journal of neuroscience, vol. 28, num. 39, p. 9723-31, 2008.

Huntington's and other polyglutamine diseases: many effects of single gene mutations.

R. Luthi-Carter. in Drug Discovery Today: Disease Mechanisms, vol. 4, num. 2, p. 111-119, 2007.

Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood.

H. Runne, A. Kuhn, E. J. Wild, W. Pratyaksha, M. Kristiansen, J. D. Isaacs, E. Régulier, M. Delorenzi, S. J. Tabrizi and R. Luthi-Carter. in Proceedings of the National Academy of Sciences of the United States of America, vol. 104, num. 36, p. 14424-9, 2007.

Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.

A. Kuhn, D. R. Goldstein, A. Hodges, A. D. Strand, T. Sengstag, C. Kooperberg, K. Becanovic, M. A. Pouladi, K. Sathasivam, J.-H. J. Cha, A. J. Hannan, M. R. Hayden, B. R. Leavitt, S. B. Dunnett, R. J. Ferrante, R. Albin, P. Shelbourne, M. Delorenzi, S. J. Augood, R. L. M. Faull, J. M. Olson, G. P. Bates, L. Jones and R. Luthi-Carter. in Human molecular genetics, vol. 16, num. 15, p. 1845-61, 2007.

Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease.

V. Perrin, E. Régulier, T. Abbas-Terki, R. Hassig, E. Brouillet, P. Aebischer, R. Luthi-Carter and N. Déglon. in Molecular Therapy, vol. 15, num. 5, p. 903-11, 2007.

Regional and cellular gene expression changes in human Huntington's disease brain.

A. Hodges, A. D. Strand, A. K. Aragaki, A. Kuhn, T. Sengstag, G. Hughes, L. A. Elliston, C. Hartog, D. R. Goldstein, D. Thu, Z. R. Hollingsworth, F. Collin, B. Synek, P. A. Holmans, A. B. Young, N. S. Wexler, M. Delorenzi, C. Kooperberg, S. J. Augood, R. L. M. Faull, J. M. Olson, L. Jones and R. Luthi-Carter. in Human molecular genetics, vol. 15, num. 6, p. 965-77, 2006.

Share this page:

Contact the Department

Department of Neuroscience, Psychology and Behaviour
University of Leicester
University Road

T: +44 (0)116 252 2922


AccessAble logo

The University of Leicester is committed to equal access to our facilities. DisabledGo has detailed accessibility guides for the George Davies Centre, the Adrian Building and the Maurice Shock Medical Sciences Building.